{"transactions":[{"id":4614041,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-09T23:24:16.000Z","date":"2026-09-09","kind":"sale","planned":false,"acquired":false,"shares":28837,"price":7.13,"value":205607.81,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the\nnumber of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735 by AM BV2018."}],"balance_after":3885115,"source":{"system":"sec-edgar","filing":"0001231919-26-001156","document":"form4-09092026_110910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818702/000123191926001156/form4-09092026_110910.xml","form_type":"4"}},{"id":4614040,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-09T23:24:16.000Z","date":"2026-09-08","kind":"sale","planned":false,"acquired":false,"shares":192500,"price":7.41,"value":1426425.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the\nnumber of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018."}],"balance_after":3913952,"source":{"system":"sec-edgar","filing":"0001231919-26-001156","document":"form4-09092026_110910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818702/000123191926001156/form4-09092026_110910.xml","form_type":"4"}},{"id":4614039,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-09T23:24:16.000Z","date":"2026-09-04","kind":"sale","planned":false,"acquired":false,"shares":38500,"price":7.11,"value":273735.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,166 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 602 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 17,942 by MPM BioVentures 2018, L.P. (\"BV\n2018\"), 954 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 354 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general\npartners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the\nmanager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the\nnumber of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4106452,"source":{"system":"sec-edgar","filing":"0001231919-26-001156","document":"form4-09092026_110910.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818702/000123191926001156/form4-09092026_110910.xml","form_type":"4"}},{"id":4614038,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-09T23:23:33.000Z","date":"2026-09-09","kind":"sale","planned":false,"acquired":false,"shares":28837,"price":7.13,"value":205607.81,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 13,095 by BV 2014, 873 by BV 2014(B), 451 by AM BV2014, 13,439 by BV 2018, 714 by BV 2018(B) and 265 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.02 to $7.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding\nthe number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,764,167 by BV 2014, 117,667 by BV 2014(B), 60,722 by AM BV2014, 1,810,592 by BV 2018, 96,232 by BV 2018(B) and 35,735  by AM BV2018."}],"balance_after":3885115,"source":{"system":"sec-edgar","filing":"0001231919-26-001155","document":"form4-09092026_110922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1765091/000123191926001155/form4-09092026_110922.xml","form_type":"4"}},{"id":4614037,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-09T23:23:33.000Z","date":"2026-09-08","kind":"sale","planned":false,"acquired":false,"shares":192500,"price":7.41,"value":1426425.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 87,411 by BV 2014, 5,830 by BV 2014(B), 3,009 by AM BV2014, 89,712 by BV 2018, 4,768 by BV 2018(B) and 1,770 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,777,262 by BV 2014, 118,540 by BV 2014(B), 61,173 by AM BV2014, 1,824,031 by BV 2018, 96,946 by BV 2018(B) and 36,000 by AM BV2018."}],"balance_after":3913952,"source":{"system":"sec-edgar","filing":"0001231919-26-001155","document":"form4-09092026_110922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1765091/000123191926001155/form4-09092026_110922.xml","form_type":"4"}},{"id":4614036,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-09T23:23:33.000Z","date":"2026-09-04","kind":"sale","planned":false,"acquired":false,"shares":38500,"price":7.11,"value":273735.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 17,482 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,166 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 602 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 17,942 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 954 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 354 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.01 to $7.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,864,673 by BV 2014, 124,370 by BV 2014(B), 64,182 by AM BV2014, 1,913,743 by BV 2018, 101,714 by BV 2018(B) and 37,770 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4106452,"source":{"system":"sec-edgar","filing":"0001231919-26-001155","document":"form4-09092026_110922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1765091/000123191926001155/form4-09092026_110922.xml","form_type":"4"}},{"id":3650,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T23:21:49.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":32263,"price":7.17,"value":231325.71,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 14,650 by BV 2014, 977 by BV 2014(B), 504 by AM BV2014, 15,036 by BV 2018, 799 by BV 2018(B) and 297 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0434 to $7.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the\nnumber of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,882,155 by BV 2014, 125,536 by BV 2014(B), 64,784 by AM BV2014, 1,931,685 by BV 2018, 102,668 by BV 2018(B) and 38,124 by AM BV2018."}],"balance_after":4144952,"source":{"system":"sec-edgar","filing":"0001231919-26-001144","document":"form4-09032026_110942.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818702/000123191926001144/form4-09032026_110942.xml","form_type":"4"}},{"id":3649,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T23:21:49.000Z","date":"2026-09-02","kind":"sale","planned":false,"acquired":false,"shares":25131,"price":7.19,"value":180691.89,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 11,412 by BV 2014, 761 by BV 2014(B), 393 by AM BV2014, 11,712 by BV 2018, 622 by BV 2018(B) and 231 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.9601 to $7.3273 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding\nthe number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,896,805 by BV 2014, 126,513 by BV 2014(B), 65,288 by AM BV2014, 1,946,721 by BV 2018, 103,467 by BV 2018(B) and 38,421 by AM BV2018."}],"balance_after":4177215,"source":{"system":"sec-edgar","filing":"0001231919-26-001144","document":"form4-09032026_110942.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818702/000123191926001144/form4-09032026_110942.xml","form_type":"4"}},{"id":3648,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T23:21:49.000Z","date":"2026-09-01","kind":"sale","planned":false,"acquired":false,"shares":29088,"price":7.06,"value":205361.28,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 13,208 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 881 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 455 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 13,556 by MPM BioVentures 2018, L.P. (\"BV\n2018\"), 720 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 268 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general\npartners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the\nmanager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.80 to $7.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the\nnumber of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,908,217 by BV 2014, 127,274 by BV 2014(B), 65,681 by AM BV2014, 1,958,433 by BV 2018, 104,089 by BV 2018(B) and 38,652 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4202346,"source":{"system":"sec-edgar","filing":"0001231919-26-001144","document":"form4-09032026_110942.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818702/000123191926001144/form4-09032026_110942.xml","form_type":"4"}},{"id":3645,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T23:21:03.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":32263,"price":7.17,"value":231325.71,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 14,650 by BV 2014, 977 by BV 2014(B), 504 by AM BV2014, 15,036 by BV 2018, 799 by BV 2018(B) and 297 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0434 to $7.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding\nthe number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,882,155 by BV 2014, 125,536 by BV 2014(B), 64,784 by AM BV2014, 1,931,685 by BV 2018, 102,668 by BV 2018(B) and 38,124 by AM BV2018."}],"balance_after":4144952,"source":{"system":"sec-edgar","filing":"0001231919-26-001143","document":"form4-09032026_110951.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1765091/000123191926001143/form4-09032026_110951.xml","form_type":"4"}},{"id":3644,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T23:21:03.000Z","date":"2026-09-02","kind":"sale","planned":false,"acquired":false,"shares":25131,"price":7.19,"value":180691.89,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 11,412 by BV 2014, 761 by BV 2014(B), 393 by AM BV2014, 11,712 by BV 2018, 622 by BV 2018(B) and 231 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.9601 to $7.3273 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,896,805 by BV 2014, 126,513 by BV 2014(B), 65,288 by AM BV2014, 1,946,721 by BV 2018, 103,467 by BV 2018(B) and 38,421 by AM BV2018."}],"balance_after":4177215,"source":{"system":"sec-edgar","filing":"0001231919-26-001143","document":"form4-09032026_110951.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1765091/000123191926001143/form4-09032026_110951.xml","form_type":"4"}},{"id":3643,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T23:21:03.000Z","date":"2026-09-01","kind":"sale","planned":false,"acquired":false,"shares":29088,"price":7.06,"value":205361.28,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 13,208 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 881 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 455 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 13,556 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 720 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 268 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.80 to $7.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,908,217 by BV 2014, 127,274 by BV 2014(B), 65,681 by AM BV2014, 1,958,433 by BV 2018, 104,089 by BV 2018(B) and 38,652 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4202346,"source":{"system":"sec-edgar","filing":"0001231919-26-001143","document":"form4-09032026_110951.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1765091/000123191926001143/form4-09032026_110951.xml","form_type":"4"}},{"id":3136,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2174,"kind":"person","name":"Doshi Dipal","position":1,"cik":"0001613084","reported_name":"Doshi Dipal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-09-03T21:19:26.000Z","date":"2026-09-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":8724,"price":7.1439,"value":62323.3836,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":517290,"source":{"system":"sec-edgar","filing":"0001613084-26-000004","document":"wk-form4_1788470363.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000161308426000004/wk-form4_1788470363.xml","form_type":"4"}},{"id":3130,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2026-09-03T21:18:14.000Z","date":"2026-09-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":2528,"price":7.1439,"value":18059.7792,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":196060,"source":{"system":"sec-edgar","filing":"0001873392-26-000006","document":"wk-form4_1788470291.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000006/wk-form4_1788470291.xml","form_type":"4"}},{"id":3125,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2164,"kind":"person","name":"Sethuraman Natarajan","position":1,"cik":"0001873394","reported_name":"Sethuraman Natarajan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Research & Develop."}}],"security":"Common Stock","published_at":"2026-09-03T21:16:25.000Z","date":"2026-09-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":2079,"price":7.1439,"value":14852.1681,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":214238,"source":{"system":"sec-edgar","filing":"0001873394-26-000005","document":"wk-form4_1788470182.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873394/000187339426000005/wk-form4_1788470182.xml","form_type":"4"}},{"id":3126,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2165,"kind":"person","name":"WENTWORTH KORY JAMES","position":1,"cik":"0001725663","reported_name":"WENTWORTH KORY JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-03T21:15:58.000Z","date":"2026-09-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":1733,"price":7.1439,"value":12380.3787,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":117277,"source":{"system":"sec-edgar","filing":"0001725663-26-000007","document":"wk-form4_1788470155.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725663/000172566326000007/wk-form4_1788470155.xml","form_type":"4"}},{"id":672082,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-31T22:26:12.000Z","date":"2026-08-31","kind":"sale","planned":false,"acquired":false,"shares":44259,"price":6.99,"value":309370.41,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 20,097 by BV 2014, 1,341 by BV 2014(B), 692 by AM BV2014, 20,626 by BV 2018, 1,096 by BV 2018(B) and 407 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.76 to $7.1626 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the\nnumber of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,921,425 by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018."}],"balance_after":4231434,"source":{"system":"sec-edgar","filing":"0001231919-26-001136","document":"form4-08312026_100804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000123191926001136/form4-08312026_100804.xml","form_type":"4"}},{"id":672081,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-31T22:26:12.000Z","date":"2026-08-28","kind":"sale","planned":false,"acquired":false,"shares":3733,"price":7.01,"value":26168.33,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 1,695 by BV 2014, 113 by BV 2014(B), 58 by AM BV2014, 1,740 by BV 2018, 93 by BV 2018(B) and 34 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.95 to $7.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the\nnumber of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,941,522 by BV 2014, 129,496 by BV 2014(B), 66,828 by AM BV2014, 1,992,615 by BV 2018, 105,905 by BV 2018(B) and 39,327 by AM BV2018."}],"balance_after":4275693,"source":{"system":"sec-edgar","filing":"0001231919-26-001136","document":"form4-08312026_100804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000123191926001136/form4-08312026_100804.xml","form_type":"4"}},{"id":672080,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-31T22:26:12.000Z","date":"2026-08-27","kind":"sale","planned":false,"acquired":false,"shares":38922,"price":7.2,"value":280238.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 17,674 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,179 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 608 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 18,139 by MPM BioVentures 2018, L.P. (\"BV\n2018\"), 964 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 358 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general\npartners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the\nmanager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.88 to $7.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the\nnumber of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,943,217 by BV 2014, 129,609 by BV 2014(B), 66,886 by AM BV2014, 1,994,355 by BV 2018, 105,998 by BV 2018(B) and 39,361 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4279426,"source":{"system":"sec-edgar","filing":"0001231919-26-001136","document":"form4-08312026_100804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000123191926001136/form4-08312026_100804.xml","form_type":"4"}},{"id":672221,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-31T22:25:04.000Z","date":"2026-08-31","kind":"sale","planned":false,"acquired":false,"shares":44259,"price":6.99,"value":309370.41,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 20,097 by BV 2014, 1,341 by BV 2014(B), 692 by AM BV2014, 20,626 by BV 2018, 1,096 by BV 2018(B) and 407 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.76 to $7.1626 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,921,425 by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018."}],"balance_after":4231434,"source":{"system":"sec-edgar","filing":"0001231919-26-001135","document":"form4-08312026_100852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926001135/form4-08312026_100852.xml","form_type":"4"}},{"id":672220,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-31T22:25:04.000Z","date":"2026-08-28","kind":"sale","planned":false,"acquired":false,"shares":3733,"price":7.01,"value":26168.33,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 1,695 by BV 2014, 113 by BV 2014(B), 58 by AM BV2014, 1,740 by BV 2018, 93 by BV 2018(B) and 34 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.95 to $7.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,941,522 by BV 2014, 129,496 by BV 2014(B), 66,828 by AM BV2014, 1,992,615 by BV 2018, 105,905 by BV 2018(B) and 39,327 by AM BV2018."}],"balance_after":4275693,"source":{"system":"sec-edgar","filing":"0001231919-26-001135","document":"form4-08312026_100852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926001135/form4-08312026_100852.xml","form_type":"4"}},{"id":672219,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-31T22:25:04.000Z","date":"2026-08-27","kind":"sale","planned":false,"acquired":false,"shares":38922,"price":7.2,"value":280238.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 17,674 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 1,179 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 608 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 18,139 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 964 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 358 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.88 to $7.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,943,217 by BV 2014, 129,609 by BV 2014(B), 66,886 by AM BV2014, 1,994,355 by BV 2018, 105,998 by BV 2018(B) and 39,361 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4279426,"source":{"system":"sec-edgar","filing":"0001231919-26-001135","document":"form4-08312026_100852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926001135/form4-08312026_100852.xml","form_type":"4"}},{"id":675339,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-27T01:28:15.000Z","date":"2026-08-26","kind":"sale","planned":false,"acquired":false,"shares":14569,"price":7.06,"value":102857.14,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 6,615 by BV 2014, 441 by BV 2014(B), 228 by AM BV2014, 6,790 by BV 2018, 361 by BV 2018(B) and 134 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,960,891 by BV 2014, 130,788 by BV 2014(B), 67,494 by AM BV2014, 2,012,494 by BV 2018, 106,962 by BV 2018(B) and 39,719 by AM BV2018."}],"balance_after":4318348,"source":{"system":"sec-edgar","filing":"0001231919-26-001107","document":"form4-08272026_010802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926001107/form4-08272026_010802.xml","form_type":"4"}},{"id":675338,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-27T01:28:15.000Z","date":"2026-08-25","kind":"sale","planned":false,"acquired":false,"shares":26522,"price":7.54,"value":199975.88,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 12,043 by BV 2014, 803 by BV 2014(B), 415 by AM BV2014, 12,360 by BV 2018, 657 by BV 2018(B) and 244 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.28 to $7.6421 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,967,506 by BV 2014, 131,229 by BV 2014(B), 67,722 by AM BV2014, 2,019,284 by BV 2018, 107,323 by BV 2018(B) and 39,853 by AM BV2018."}],"balance_after":4332917,"source":{"system":"sec-edgar","filing":"0001231919-26-001107","document":"form4-08272026_010802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926001107/form4-08272026_010802.xml","form_type":"4"}},{"id":675337,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2479,"kind":"organization","name":"MPM BioVentures 2014, L.P.","position":1,"cik":"0001609492","reported_name":"MPM BioVentures 2014, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2480,"kind":"person","name":"EVNIN LUKE","position":2,"cik":"0001134657","reported_name":"EVNIN LUKE","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":3,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2482,"kind":"person","name":"Foley Todd","position":4,"cik":"0001473930","reported_name":"Foley Todd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2483,"kind":"organization","name":"MPM BioVentures 2014 (B), L.P.","position":5,"cik":"0001609493","reported_name":"MPM BioVentures 2014 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2484,"kind":"organization","name":"MPM Asset Management Investors BV2014 LLC","position":6,"cik":"0001609495","reported_name":"MPM Asset Management Investors BV2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2485,"kind":"organization","name":"MPM BioVentures 2014 LLC","position":7,"cik":"0001765021","reported_name":"MPM BioVentures 2014 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2486,"kind":"organization","name":"MPM BioVentures 2014 GP LLC","position":8,"cik":"0001765091","reported_name":"MPM BioVentures 2014 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2487,"kind":"organization","name":"MPM BIOVENTURES 2018 (B), L.P.","position":9,"cik":"0001729504","reported_name":"MPM BIOVENTURES 2018 (B), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2488,"kind":"organization","name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","position":10,"cik":"0001734817","reported_name":"MPM ASSET MANAGEMENT INVESTORS BV2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-27T01:28:15.000Z","date":"2026-08-24","kind":"sale","planned":false,"acquired":false,"shares":21623,"price":7.34,"value":158712.82,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 9,819 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 655 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 338 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 10,077 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 535 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 199 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0852 to $7.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,979,549 by BV 2014, 132,032 by BV 2014(B), 68,137 by AM BV2014, 2,031,644 by BV 2018, 107,980 by BV 2018(B) and 40,097 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4359439,"source":{"system":"sec-edgar","filing":"0001231919-26-001107","document":"form4-08272026_010802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000123191926001107/form4-08272026_010802.xml","form_type":"4"}},{"id":675135,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-27T01:27:36.000Z","date":"2026-08-26","kind":"sale","planned":false,"acquired":false,"shares":14569,"price":7.06,"value":102857.14,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 6,615 by BV 2014, 441 by BV 2014(B), 228 by AM BV2014, 6,790 by BV 2018, 361 by BV 2018(B) and 134 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.97 to $7.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 1,960,891 by BV 2014, 130,788 by BV 2014(B), 67,494 by AM BV2014, 2,012,494 by BV 2018, 106,962 by BV 2018(B) and 39,719 by AM BV2018."}],"balance_after":4318348,"source":{"system":"sec-edgar","filing":"0001231919-26-001106","document":"form4-08272026_010830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000123191926001106/form4-08272026_010830.xml","form_type":"4"}},{"id":675134,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-27T01:27:36.000Z","date":"2026-08-25","kind":"sale","planned":false,"acquired":false,"shares":26522,"price":7.54,"value":199975.88,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows: 12,043 by BV 2014, 803 by BV 2014(B), 415 by AM BV2014, 12,360 by BV 2018, 657 by BV 2018(B) and 244 by AM BV2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.28 to $7.6421 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding\nthe number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 1,967,506 by BV 2014, 131,229 by BV 2014(B), 67,722 by AM BV2014, 2,019,284 by BV 2018, 107,323 by BV 2018(B) and 39,853 by AM BV2018."}],"balance_after":4332917,"source":{"system":"sec-edgar","filing":"0001231919-26-001106","document":"form4-08272026_010830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000123191926001106/form4-08272026_010830.xml","form_type":"4"}},{"id":675133,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2490,"kind":"organization","name":"MPM BIOVENTURES 2018, L.P.","position":1,"cik":"0001729505","reported_name":"MPM BIOVENTURES 2018, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2491,"kind":"organization","name":"MPM BioVentures 2018 LLC","position":2,"cik":"0001818702","reported_name":"MPM BioVentures 2018 LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2492,"kind":"organization","name":"MPM BioVentures 2018 GP LLC","position":3,"cik":"0001818701","reported_name":"MPM BioVentures 2018 GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-27T01:27:36.000Z","date":"2026-08-24","kind":"sale","planned":false,"acquired":false,"shares":21623,"price":7.34,"value":158712.82,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold as follows: 9,819 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 655 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 338 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 10,077 by MPM BioVentures 2018, L.P. (\"BV\n2018\"), 535 by MPM BioVentures 2018 (B), L.P. (\"BV 2018(B)\") and 199 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV2014 LLC\") are the direct and indirect general\npartners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the\nmanager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0852 to $7.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding\nthe number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held as follows: 1,979,549 by BV 2014, 132,032 by BV 2014(B), 68,137 by AM BV2014, 2,031,644 by BV 2018, 107,980 by BV 2018(B) and 40,097 by AM BV2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":4359439,"source":{"system":"sec-edgar","filing":"0001231919-26-001106","document":"form4-08272026_010830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818701/000123191926001106/form4-08272026_010830.xml","form_type":"4"}},{"id":691896,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T23:54:40.000Z","date":"2026-08-10","kind":"sale","planned":false,"acquired":false,"shares":92444,"price":7,"value":647108.0,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.84 to $7.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein."}],"balance_after":2691337,"source":{"system":"sec-edgar","filing":"0001664281-26-000004","document":"form4-08102026_110836.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000166428126000004/form4-08102026_110836.xml","form_type":"4"}},{"id":691895,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T23:54:40.000Z","date":"2026-08-07","kind":"sale","planned":false,"acquired":false,"shares":52317,"price":6.85,"value":358371.45,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.80 to $7.01 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":2783781,"source":{"system":"sec-edgar","filing":"0001664281-26-000004","document":"form4-08102026_110836.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000166428126000004/form4-08102026_110836.xml","form_type":"4"}},{"id":691894,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T23:54:40.000Z","date":"2026-08-06","kind":"sale","planned":false,"acquired":false,"shares":10494,"price":7,"value":73458.0,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.90 to $7.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein."}],"balance_after":2836098,"source":{"system":"sec-edgar","filing":"0001664281-26-000004","document":"form4-08102026_110836.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000166428126000004/form4-08102026_110836.xml","form_type":"4"}},{"id":691893,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T23:52:46.000Z","date":"2026-08-07","kind":"sale","planned":false,"acquired":false,"shares":52317,"price":6.85,"value":358371.45,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.80 to $7.01 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":2783781,"source":{"system":"sec-edgar","filing":"0001231919-26-000854","document":"form4-08102026_110837.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000123191926000854/form4-08102026_110837.xml","form_type":"4"}},{"id":691892,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T23:52:46.000Z","date":"2026-08-06","kind":"sale","planned":false,"acquired":false,"shares":10494,"price":7,"value":73458.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.90 to $7.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":2836098,"source":{"system":"sec-edgar","filing":"0001231919-26-000854","document":"form4-08102026_110837.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000123191926000854/form4-08102026_110837.xml","form_type":"4"}},{"id":698835,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-03T21:32:54.000Z","date":"2026-07-31","kind":"sale","planned":false,"acquired":false,"shares":1718,"price":6.85,"value":11768.3,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":2846592,"source":{"system":"sec-edgar","filing":"0001231919-26-000822","document":"form4-08032026_090845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000123191926000822/form4-08032026_090845.xml","form_type":"4"}},{"id":698834,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-03T21:32:54.000Z","date":"2026-07-30","kind":"sale","planned":false,"acquired":false,"shares":114756,"price":6.93,"value":795259.08,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.75 to $6.95 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":2848310,"source":{"system":"sec-edgar","filing":"0001231919-26-000822","document":"form4-08032026_090845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000123191926000822/form4-08032026_090845.xml","form_type":"4"}},{"id":698833,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-03T21:26:41.000Z","date":"2026-07-31","kind":"sale","planned":false,"acquired":false,"shares":1718,"price":6.85,"value":11768.3,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"balance_after":2846592,"source":{"system":"sec-edgar","filing":"0001664281-26-000002","document":"form4-08032026_090837.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000166428126000002/form4-08032026_090837.xml","form_type":"4"}},{"id":698832,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-03T21:26:41.000Z","date":"2026-07-30","kind":"sale","planned":false,"acquired":false,"shares":114756,"price":6.93,"value":795259.08,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.75 to $6.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein."}],"balance_after":2848310,"source":{"system":"sec-edgar","filing":"0001664281-26-000002","document":"form4-08032026_090837.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000166428126000002/form4-08032026_090837.xml","form_type":"4"}},{"id":739830,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T21:34:51.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders."}],"balance_after":19000,"derivative":{"exercise_price":5.97,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001689375-26-000047","document":"wk-form4_1781300088.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937526000047/wk-form4_1781300088.xml","form_type":"4"}},{"id":740237,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":35728,"kind":"person","name":"Radhakrishnan Maha","position":1,"cik":"0002013423","reported_name":"Radhakrishnan Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T21:05:49.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders."}],"balance_after":19000,"derivative":{"exercise_price":5.97,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0002013423-26-000002","document":"wk-form4_1781298346.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2013423/000201342326000002/wk-form4_1781298346.xml","form_type":"4"}},{"id":739825,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":29279,"kind":"person","name":"Thistle Mary","position":1,"cik":"0001317917","reported_name":"Thistle Mary","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T21:01:17.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders."}],"balance_after":19000,"derivative":{"exercise_price":5.97,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001689375-26-000036","document":"wk-form4_1781298072.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937526000036/wk-form4_1781298072.xml","form_type":"4"}},{"id":740029,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":12754,"kind":"person","name":"KIM PETER S","position":1,"cik":"0001181180","reported_name":"KIM PETER S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T17:17:22.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders."}],"balance_after":19000,"derivative":{"exercise_price":5.97,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001689375-26-000044","document":"wk-form4_1781299039.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1181180/000168937526000044/wk-form4_1781299039.xml","form_type":"4"}},{"id":740222,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":38855,"kind":"person","name":"Chapman Gina","position":1,"cik":"0001989220","reported_name":"Chapman Gina","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T17:16:38.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders."}],"balance_after":19000,"derivative":{"exercise_price":5.97,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001689375-26-000043","document":"wk-form4_1781298996.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1989220/000168937526000043/wk-form4_1781298996.xml","form_type":"4"}},{"id":740219,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":38851,"kind":"person","name":"Zeiher Bernhardt G","position":1,"cik":"0001971421","reported_name":"Zeiher Bernhardt G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T16:52:10.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders."}],"balance_after":19000,"derivative":{"exercise_price":5.97,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001689375-26-000034","document":"wk-form4_1781297526.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971421/000168937526000034/wk-form4_1781297526.xml","form_type":"4"}},{"id":768243,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":38851,"kind":"person","name":"Zeiher Bernhardt G","position":1,"cik":"0001971421","reported_name":"Zeiher Bernhardt G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T16:31:31.000Z","date":"2026-05-20","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":5.8632,"value":29316.0,"ownership":{"direct":false,"nature":"By Bernhardt G Zeiher and Paula B Zeiher Revocable Living Trust Agreement"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.86 to $6.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001689375-26-000030","document":"wk-form4_1779395488.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971421/000168937526000030/wk-form4_1779395488.xml","form_type":"4"}},{"id":793965,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2164,"kind":"person","name":"Sethuraman Natarajan","position":1,"cik":"0001873394","reported_name":"Sethuraman Natarajan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Research & Develop."}}],"security":"Common Stock","published_at":"2026-05-04T23:25:01.000Z","date":"2026-05-04","kind":"sale","planned":true,"acquired":false,"shares":25907,"price":15.3939,"value":398809.7673,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.6150, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":216317,"source":{"system":"sec-edgar","filing":"0001873394-26-000003","document":"wk-form4_1777937098.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873394/000187339426000003/wk-form4_1777937098.xml","form_type":"4"}},{"id":794602,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-04T23:24:16.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option fully vested on November 4, 2023."}],"balance_after":49831,"derivative":{"exercise_price":1.74,"expiration_date":"2029-12-10","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001873392-26-000004","document":"wk-form4_1777937054.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000004/wk-form4_1777937054.xml","form_type":"4"}},{"id":794601,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2026-05-04T23:24:16.000Z","date":"2026-05-04","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":15.3302,"value":229953.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":198588,"source":{"system":"sec-edgar","filing":"0001873392-26-000004","document":"wk-form4_1777937054.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000004/wk-form4_1777937054.xml","form_type":"4"}},{"id":794600,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2026-05-04T23:24:16.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":1.74,"value":26100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025."}],"balance_after":213588,"source":{"system":"sec-edgar","filing":"0001873392-26-000004","document":"wk-form4_1777937054.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000004/wk-form4_1777937054.xml","form_type":"4"}},{"id":819602,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2165,"kind":"person","name":"WENTWORTH KORY JAMES","position":1,"cik":"0001725663","reported_name":"WENTWORTH KORY JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-02T20:39:16.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":12.95,"value":32375.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025."}],"balance_after":119010,"source":{"system":"sec-edgar","filing":"0001725663-26-000005","document":"wk-form4_1775162353.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000172566326000005/wk-form4_1775162353.xml","form_type":"4"}},{"id":849646,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2026-03-11T20:35:13.000Z","date":"2026-03-10","kind":"sale","planned":true,"acquired":false,"shares":11894,"price":13.0476,"value":155188.1544,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":198588,"source":{"system":"sec-edgar","filing":"0001873392-26-000002","document":"wk-form4_1773261310.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000002/wk-form4_1773261310.xml","form_type":"4"}},{"id":849645,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2026-03-11T20:35:13.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":3116,"price":13.024,"value":40582.784,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":210482,"source":{"system":"sec-edgar","filing":"0001873392-26-000002","document":"wk-form4_1773261310.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000002/wk-form4_1773261310.xml","form_type":"4"}},{"id":848681,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2165,"kind":"person","name":"WENTWORTH KORY JAMES","position":1,"cik":"0001725663","reported_name":"WENTWORTH KORY JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-11T20:34:08.000Z","date":"2026-03-10","kind":"sale","planned":true,"acquired":false,"shares":11388,"price":13.0151,"value":148215.9588,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.95 to $13.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":121510,"source":{"system":"sec-edgar","filing":"0001725663-26-000003","document":"wk-form4_1773261246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000172566326000003/wk-form4_1773261246.xml","form_type":"4"}},{"id":848680,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2165,"kind":"person","name":"WENTWORTH KORY JAMES","position":1,"cik":"0001725663","reported_name":"WENTWORTH KORY JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-11T20:34:08.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":5089,"price":13.0011,"value":66162.5979,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.95 to $13.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":132898,"source":{"system":"sec-edgar","filing":"0001725663-26-000003","document":"wk-form4_1773261246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000172566326000003/wk-form4_1773261246.xml","form_type":"4"}},{"id":855891,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2165,"kind":"person","name":"WENTWORTH KORY JAMES","position":1,"cik":"0001725663","reported_name":"WENTWORTH KORY JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-06T21:36:45.000Z","date":"2026-03-04","kind":"sale","planned":true,"acquired":false,"shares":7988,"price":12.2549,"value":97892.1412,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":137987,"source":{"system":"sec-edgar","filing":"0001725663-26-000002","document":"wk-form4_1772833002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000172566326000002/wk-form4_1772833002.xml","form_type":"4"}},{"id":867239,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2174,"kind":"person","name":"Doshi Dipal","position":1,"cik":"0001613084","reported_name":"Doshi Dipal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T23:21:25.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":208000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030."}],"balance_after":208000,"derivative":{"exercise_price":11.93,"expiration_date":"2036-03-01","underlying":"Common Stock","underlying_shares":208000},"source":{"system":"sec-edgar","filing":"0001613084-26-000001","document":"wk-form4_1772580082.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000161308426000001/wk-form4_1772580082.xml","form_type":"4"}},{"id":867238,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2174,"kind":"person","name":"Doshi Dipal","position":1,"cik":"0001613084","reported_name":"Doshi Dipal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-03-03T23:21:25.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":19181,"price":11.7564,"value":225499.5084,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":526014,"source":{"system":"sec-edgar","filing":"0001613084-26-000001","document":"wk-form4_1772580082.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000161308426000001/wk-form4_1772580082.xml","form_type":"4"}},{"id":867237,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2174,"kind":"person","name":"Doshi Dipal","position":1,"cik":"0001613084","reported_name":"Doshi Dipal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-03-03T23:21:25.000Z","date":"2026-03-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":9869,"price":11.6579,"value":115051.8151,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":545195,"source":{"system":"sec-edgar","filing":"0001613084-26-000001","document":"wk-form4_1772580082.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000161308426000001/wk-form4_1772580082.xml","form_type":"4"}},{"id":867236,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2174,"kind":"person","name":"Doshi Dipal","position":1,"cik":"0001613084","reported_name":"Doshi Dipal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-03-03T23:21:25.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":139400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."}],"balance_after":555064,"source":{"system":"sec-edgar","filing":"0001613084-26-000001","document":"wk-form4_1772580082.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000161308426000001/wk-form4_1772580082.xml","form_type":"4"}},{"id":867243,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2165,"kind":"person","name":"WENTWORTH KORY JAMES","position":1,"cik":"0001725663","reported_name":"WENTWORTH KORY JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T23:20:35.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":66600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030."}],"balance_after":66600,"derivative":{"exercise_price":11.93,"expiration_date":"2036-03-01","underlying":"Common Stock","underlying_shares":66600},"source":{"system":"sec-edgar","filing":"0001725663-26-000001","document":"wk-form4_1772580032.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000172566326000001/wk-form4_1772580032.xml","form_type":"4"}},{"id":867242,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2165,"kind":"person","name":"WENTWORTH KORY JAMES","position":1,"cik":"0001725663","reported_name":"WENTWORTH KORY JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T23:20:35.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":5712,"price":11.7564,"value":67152.5568,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":145975,"source":{"system":"sec-edgar","filing":"0001725663-26-000001","document":"wk-form4_1772580032.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000172566326000001/wk-form4_1772580032.xml","form_type":"4"}},{"id":867241,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2165,"kind":"person","name":"WENTWORTH KORY JAMES","position":1,"cik":"0001725663","reported_name":"WENTWORTH KORY JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T23:20:35.000Z","date":"2026-03-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":2939,"price":11.6579,"value":34262.5681,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":151687,"source":{"system":"sec-edgar","filing":"0001725663-26-000001","document":"wk-form4_1772580032.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000172566326000001/wk-form4_1772580032.xml","form_type":"4"}},{"id":867240,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2165,"kind":"person","name":"WENTWORTH KORY JAMES","position":1,"cik":"0001725663","reported_name":"WENTWORTH KORY JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T23:20:35.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":44600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."}],"balance_after":154626,"source":{"system":"sec-edgar","filing":"0001725663-26-000001","document":"wk-form4_1772580032.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000172566326000001/wk-form4_1772580032.xml","form_type":"4"}},{"id":871295,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T23:19:52.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":83200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030."}],"balance_after":83200,"derivative":{"exercise_price":11.93,"expiration_date":"2036-03-01","underlying":"Common Stock","underlying_shares":83200},"source":{"system":"sec-edgar","filing":"0001873392-26-000001","document":"wk-form4_1772579989.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000001/wk-form4_1772579989.xml","form_type":"4"}},{"id":871294,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2026-03-03T23:19:52.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":14038,"price":11.7564,"value":165036.3432,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":213598,"source":{"system":"sec-edgar","filing":"0001873392-26-000001","document":"wk-form4_1772579989.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000001/wk-form4_1772579989.xml","form_type":"4"}},{"id":871293,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2026-03-03T23:19:52.000Z","date":"2026-03-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":7223,"price":11.6579,"value":84205.0117,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":227636,"source":{"system":"sec-edgar","filing":"0001873392-26-000001","document":"wk-form4_1772579989.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000001/wk-form4_1772579989.xml","form_type":"4"}},{"id":871292,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2026-03-03T23:19:52.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":55800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."}],"balance_after":234859,"source":{"system":"sec-edgar","filing":"0001873392-26-000001","document":"wk-form4_1772579989.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339226000001/wk-form4_1772579989.xml","form_type":"4"}},{"id":868203,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2164,"kind":"person","name":"Sethuraman Natarajan","position":1,"cik":"0001873394","reported_name":"Sethuraman Natarajan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Research & Develop."}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T23:18:54.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":83200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030."}],"balance_after":83200,"derivative":{"exercise_price":11.93,"expiration_date":"2036-03-01","underlying":"Common Stock","underlying_shares":83200},"source":{"system":"sec-edgar","filing":"0001873394-26-000001","document":"wk-form4_1772579932.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1873394/000187339426000001/wk-form4_1772579932.xml","form_type":"4"}},{"id":868202,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2164,"kind":"person","name":"Sethuraman Natarajan","position":1,"cik":"0001873394","reported_name":"Sethuraman Natarajan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Research & Develop."}}],"security":"Common Stock","published_at":"2026-03-03T23:18:54.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":7577,"price":11.7564,"value":89078.2428,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":242224,"source":{"system":"sec-edgar","filing":"0001873394-26-000001","document":"wk-form4_1772579932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1873394/000187339426000001/wk-form4_1772579932.xml","form_type":"4"}},{"id":868201,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2164,"kind":"person","name":"Sethuraman Natarajan","position":1,"cik":"0001873394","reported_name":"Sethuraman Natarajan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Research & Develop."}}],"security":"Common Stock","published_at":"2026-03-03T23:18:54.000Z","date":"2026-03-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":3898,"price":11.6579,"value":45442.4942,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":249801,"source":{"system":"sec-edgar","filing":"0001873394-26-000001","document":"wk-form4_1772579932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1873394/000187339426000001/wk-form4_1772579932.xml","form_type":"4"}},{"id":868200,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2164,"kind":"person","name":"Sethuraman Natarajan","position":1,"cik":"0001873394","reported_name":"Sethuraman Natarajan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Research & Develop."}}],"security":"Common Stock","published_at":"2026-03-03T23:18:54.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":55800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."}],"balance_after":253699,"source":{"system":"sec-edgar","filing":"0001873394-26-000001","document":"wk-form4_1772579932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873394/000187339426000001/wk-form4_1772579932.xml","form_type":"4"}},{"id":990035,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2165,"kind":"person","name":"WENTWORTH KORY JAMES","position":1,"cik":"0001725663","reported_name":"WENTWORTH KORY JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-24T21:30:41.000Z","date":"2025-11-21","kind":"sale","planned":true,"acquired":false,"shares":8910,"price":9.9811,"value":88931.601,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":110026,"source":{"system":"sec-edgar","filing":"0001725663-25-000004","document":"wk-form4_1764019838.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000172566325000004/wk-form4_1764019838.xml","form_type":"4"}},{"id":990558,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-24T21:09:49.000Z","date":"2025-11-20","kind":"purchase","planned":false,"acquired":true,"shares":13082,"price":9.0728,"value":118690.3696,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $8.85 to $9.20, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":4691392,"source":{"system":"sec-edgar","filing":"0001193125-25-293698","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525293698/ownership.xml","form_type":"4"}},{"id":990557,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-24T21:09:49.000Z","date":"2025-11-20","kind":"purchase","planned":false,"acquired":true,"shares":1186,"price":9.0728,"value":10760.3408,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $8.85 to $9.20, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":381338,"source":{"system":"sec-edgar","filing":"0001193125-25-293698","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525293698/ownership.xml","form_type":"4"}},{"id":990556,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-24T21:09:49.000Z","date":"2025-11-20","kind":"purchase","planned":false,"acquired":true,"shares":13386,"price":9.0688,"value":121394.9568,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of Entrada Therapeutics, Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $8.82 to $9.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":4678310,"source":{"system":"sec-edgar","filing":"0001193125-25-293698","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525293698/ownership.xml","form_type":"4"}},{"id":990555,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-24T21:09:49.000Z","date":"2025-11-20","kind":"purchase","planned":false,"acquired":true,"shares":1213,"price":9.0688,"value":11000.4544,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of Entrada Therapeutics, Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $8.82 to $9.25, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":380152,"source":{"system":"sec-edgar","filing":"0001193125-25-293698","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525293698/ownership.xml","form_type":"4"}},{"id":995782,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-18T21:36:30.000Z","date":"2025-11-14","kind":"sale","planned":false,"acquired":false,"shares":200000,"price":8.8,"value":1760000.0,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $9.023 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein."}],"balance_after":2963066,"source":{"system":"sec-edgar","filing":"0001664281-25-000003","document":"form4-11182025_091127.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000166428125000003/form4-11182025_091127.xml","form_type":"4"}},{"id":995783,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-18T21:34:52.000Z","date":"2025-11-14","kind":"sale","planned":false,"acquired":false,"shares":200000,"price":8.8,"value":1760000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $9.023 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":2963066,"source":{"system":"sec-edgar","filing":"0001231919-25-000522","document":"form4-11182025_091144.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000123191925000522/form4-11182025_091144.xml","form_type":"4"}},{"id":1002737,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T22:34:18.000Z","date":"2025-11-12","kind":"purchase","planned":false,"acquired":true,"shares":11494,"price":7.9547,"value":91431.3218,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $7.90 to $8.00, inclusive. The reporting persons undertake to provide to the\nIssuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":4664924,"source":{"system":"sec-edgar","filing":"0001193125-25-278038","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525278038/ownership.xml","form_type":"4"}},{"id":1002736,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T22:34:18.000Z","date":"2025-11-12","kind":"purchase","planned":false,"acquired":true,"shares":1040,"price":7.9547,"value":8272.888,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $7.90 to $8.00, inclusive. The reporting persons undertake to provide to the\nIssuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":378939,"source":{"system":"sec-edgar","filing":"0001193125-25-278038","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525278038/ownership.xml","form_type":"4"}},{"id":1002735,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T22:34:18.000Z","date":"2025-11-12","kind":"purchase","planned":false,"acquired":true,"shares":80881,"price":7.7315,"value":625331.4515,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $7.44 to $8.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":4653430,"source":{"system":"sec-edgar","filing":"0001193125-25-278038","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525278038/ownership.xml","form_type":"4"}},{"id":1002734,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T22:34:18.000Z","date":"2025-11-12","kind":"purchase","planned":false,"acquired":true,"shares":7321,"price":7.7315,"value":56602.3115,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $7.44 to $8.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":377899,"source":{"system":"sec-edgar","filing":"0001193125-25-278038","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525278038/ownership.xml","form_type":"4"}},{"id":1002733,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T22:34:18.000Z","date":"2025-11-11","kind":"purchase","planned":false,"acquired":true,"shares":30879,"price":7.5395,"value":232812.2205,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $7.33 to $7.74, inclusive. The reporting persons undertake to provide to the\nIssuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":4572549,"source":{"system":"sec-edgar","filing":"0001193125-25-278038","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525278038/ownership.xml","form_type":"4"}},{"id":1002732,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T22:34:18.000Z","date":"2025-11-11","kind":"purchase","planned":false,"acquired":true,"shares":2795,"price":7.5395,"value":21072.9025,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $7.33 to $7.74, inclusive. The reporting persons undertake to provide to the\nIssuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":370578,"source":{"system":"sec-edgar","filing":"0001193125-25-278038","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525278038/ownership.xml","form_type":"4"}},{"id":1002731,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T22:34:18.000Z","date":"2025-11-11","kind":"purchase","planned":false,"acquired":true,"shares":11701,"price":7.3909,"value":86480.9209,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $7.35 to $7.65, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":4541670,"source":{"system":"sec-edgar","filing":"0001193125-25-278038","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525278038/ownership.xml","form_type":"4"}},{"id":1002730,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T22:34:18.000Z","date":"2025-11-11","kind":"purchase","planned":false,"acquired":true,"shares":1059,"price":7.3909,"value":7826.9631,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $7.35 to $7.65, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":367783,"source":{"system":"sec-edgar","filing":"0001193125-25-278038","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525278038/ownership.xml","form_type":"4"}},{"id":1002729,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T22:34:18.000Z","date":"2025-11-10","kind":"purchase","planned":false,"acquired":true,"shares":2947,"price":7.2244,"value":21290.3068,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $7.06 to $7.32, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":4529969,"source":{"system":"sec-edgar","filing":"0001193125-25-278038","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525278038/ownership.xml","form_type":"4"}},{"id":1002728,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T22:34:18.000Z","date":"2025-11-10","kind":"purchase","planned":false,"acquired":true,"shares":267,"price":7.2244,"value":1928.9148,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $7.06 to $7.32, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":366724,"source":{"system":"sec-edgar","filing":"0001193125-25-278038","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525278038/ownership.xml","form_type":"4"}},{"id":1002727,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T22:34:18.000Z","date":"2025-11-10","kind":"purchase","planned":false,"acquired":true,"shares":25364,"price":7.2139,"value":182973.3596,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of Entrada Therapeutics, Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $6.96 to $7.29, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":4527022,"source":{"system":"sec-edgar","filing":"0001193125-25-278038","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525278038/ownership.xml","form_type":"4"}},{"id":1002726,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T22:34:18.000Z","date":"2025-11-10","kind":"purchase","planned":false,"acquired":true,"shares":2296,"price":7.2139,"value":16563.1144,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of Entrada Therapeutics, Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $6.96 to $7.29, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":366457,"source":{"system":"sec-edgar","filing":"0001193125-25-278038","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312525278038/ownership.xml","form_type":"4"}},{"id":1047925,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2174,"kind":"person","name":"Doshi Dipal","position":1,"cik":"0001613084","reported_name":"Doshi Dipal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-09-04T21:04:40.000Z","date":"2025-09-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":8723,"price":5.4302,"value":47367.6346,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":415664,"source":{"system":"sec-edgar","filing":"0001613084-25-000003","document":"wk-form4_1757019877.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000161308425000003/wk-form4_1757019877.xml","form_type":"4"}},{"id":1048792,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2170,"kind":"person","name":"Dowden Nathan J","position":1,"cik":"0001873392","reported_name":"Dowden Nathan J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2025-09-04T21:03:44.000Z","date":"2025-09-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":1746,"price":5.4302,"value":9481.1292,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":179059,"source":{"system":"sec-edgar","filing":"0001873392-25-000003","document":"wk-form4_1757019821.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873392/000187339225000003/wk-form4_1757019821.xml","form_type":"4"}},{"id":1048109,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2164,"kind":"person","name":"Sethuraman Natarajan","position":1,"cik":"0001873394","reported_name":"Sethuraman Natarajan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Research & Develop."}}],"security":"Common Stock","published_at":"2025-09-04T21:03:05.000Z","date":"2025-09-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":1760,"price":5.4302,"value":9557.152,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":197899,"source":{"system":"sec-edgar","filing":"0001873394-25-000003","document":"wk-form4_1757019782.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873394/000187339425000003/wk-form4_1757019782.xml","form_type":"4"}},{"id":1047927,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":2165,"kind":"person","name":"WENTWORTH KORY JAMES","position":1,"cik":"0001725663","reported_name":"WENTWORTH KORY JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-04T21:02:01.000Z","date":"2025-09-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":1734,"price":5.4302,"value":9415.9668,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":118936,"source":{"system":"sec-edgar","filing":"0001725663-25-000003","document":"wk-form4_1757019718.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000172566325000003/wk-form4_1757019718.xml","form_type":"4"}},{"id":1088600,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-11T21:27:03.000Z","date":"2025-07-09","kind":"sale","planned":false,"acquired":false,"shares":6935,"price":7.502,"value":52026.37,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein."}],"balance_after":1093313,"source":{"system":"sec-edgar","filing":"0001415889-25-019680","document":"form4-07112025_090759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925019680/form4-07112025_090759.xml","form_type":"4"}},{"id":1088599,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-11T21:27:03.000Z","date":"2025-07-09","kind":"sale","planned":false,"acquired":false,"shares":20065,"price":7.502,"value":150527.63,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein."}],"balance_after":3163066,"source":{"system":"sec-edgar","filing":"0001415889-25-019680","document":"form4-07112025_090759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925019680/form4-07112025_090759.xml","form_type":"4"}},{"id":1088592,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-11T21:25:21.000Z","date":"2025-07-09","kind":"sale","planned":false,"acquired":false,"shares":6935,"price":7.502,"value":52026.37,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":1093313,"source":{"system":"sec-edgar","filing":"0001415889-25-019677","document":"form4-07112025_090716.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925019677/form4-07112025_090716.xml","form_type":"4"}},{"id":1088591,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":25023,"kind":"organization","name":"5AM Ventures V, L.P.","position":1,"cik":"0001674324","reported_name":"5AM Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25024,"kind":"organization","name":"5AM Partners V, LLC","position":2,"cik":"0001791889","reported_name":"5AM Partners V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25025,"kind":"organization","name":"5AM Opportunities I, L.P.","position":3,"cik":"0001753000","reported_name":"5AM Opportunities I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25026,"kind":"organization","name":"5AM Opportunities I (GP), LLC","position":4,"cik":"0001790778","reported_name":"5AM Opportunities I (GP), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21277,"kind":"person","name":"ROCKLAGE SCOTT M","position":5,"cik":"0001219014","reported_name":"ROCKLAGE SCOTT M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":18314,"kind":"person","name":"Schwab Andrew J.","position":6,"cik":"0001598549","reported_name":"Schwab Andrew J.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-11T21:25:21.000Z","date":"2025-07-09","kind":"sale","planned":false,"acquired":false,"shares":20065,"price":7.502,"value":150527.63,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports."}],"balance_after":3163066,"source":{"system":"sec-edgar","filing":"0001415889-25-019677","document":"form4-07112025_090716.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925019677/form4-07112025_090716.xml","form_type":"4"}},{"id":1097862,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T00:33:41.000Z","date":"2025-07-01","kind":"sale","planned":false,"acquired":false,"shares":6422,"price":7.1226,"value":45741.3372,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein."}],"balance_after":1100248,"source":{"system":"sec-edgar","filing":"0001415889-25-018824","document":"form4-07022025_120738.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925018824/form4-07022025_120738.xml","form_type":"4"}},{"id":1097861,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T00:33:41.000Z","date":"2025-07-01","kind":"sale","planned":false,"acquired":false,"shares":18578,"price":7.1226,"value":132323.6628,"ownership":{"direct":false,"nature":"By 5AM Ventures V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by 5AM Ventures V, L.P. (\"5AM V\"). 5AM Partners V, LLC (\"5AM Partners\") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein."}],"balance_after":3183131,"source":{"system":"sec-edgar","filing":"0001415889-25-018824","document":"form4-07022025_120738.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925018824/form4-07022025_120738.xml","form_type":"4"}},{"id":1097860,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":21276,"kind":"person","name":"PARMAR KUSH","position":1,"cik":"0001664281","reported_name":"PARMAR KUSH","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T00:33:41.000Z","date":"2025-06-30","kind":"sale","planned":false,"acquired":false,"shares":6422,"price":6.8127,"value":43751.1594,"ownership":{"direct":false,"nature":"By 5AM Opportunities I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by 5AM Opportunities I, L.P. (\"Opportunities\"). 5AM Opportunities I (GP), LLC (\"Opportunities GP\") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein."}],"balance_after":1106670,"source":{"system":"sec-edgar","filing":"0001415889-25-018824","document":"form4-07022025_120738.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000141588925018824/form4-07022025_120738.xml","form_type":"4"}}],"next_cursor":"2025-07-02T00:33:41.000000Z,1097860"}